Clinical Development of AAVCOVID: A Single Dose AAV-Based Vaccine for COVID-19

Time: 9:30 am
day: Day Two

Details:

  • Understanding how AAVCOVID induces potent neutralizing SARS-CoV-2 antibodies following a single dose intramuscular injection
  • Developing insight into how AAVCOVID can be manufactured at scale with established industry AAV production processes
  • The AAVCOVID vaccine has minimal cold-chain requirements, with stability at room temperature for at least 1 month

Speakers: